Mexico Cancer Supportive Care Drugs Market Size & Outlook

The cancer supportive care drugs market in Mexico is expected to reach a projected revenue of US$ 206.9 million by 2030. A compound annual growth rate of -1.5% is expected of Mexico cancer supportive care drugs market from 2024 to 2030.
Revenue, 2023 (US$M)
$229.5
Forecast, 2030 (US$M)
$206.9
CAGR, 2024 - 2030
-1.5%
Report Coverage
Mexico

Mexico cancer supportive care drugs market highlights

  • The Mexico cancer supportive care drugs market generated a revenue of USD 229.5 million in 2023 and is expected to reach USD 206.9 million by 2030.
  • The Mexico market is expected to grow at a CAGR of -1.5% from 2024 to 2030.
  • In terms of segment, opioids was the largest revenue generating therapeutic class in 2023.
  • NSAIDs and Others is the most lucrative therapeutic class segment registering the fastest growth during the forecast period.


Cancer supportive care drugs market data book summary

Market revenue in 2023USD 229.5 million
Market revenue in 2030USD 206.9 million
Growth rate-1.5% (CAGR from 2023 to 2030)
Largest segmentOpioids
Fastest growing segmentNSAIDs and Others
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationG-CSFs (Granulocyte-colony Stimulating Factors), ESAs (Erythropoiesis Stimulating Agents), Antiemetics, Bisphosphonates, Opioids, NSAIDs and Others
Key market players worldwideAmgen Inc, Merck & Co Inc, Johnson & Johnson, Heron Therapeutics Inc, Novartis AG ADR, GSK PLC, Roche Holding AG ADR, Helsinn Healthcare


Other key industry trends

  • In terms of revenue, Mexico accounted for 1.7% of the global cancer supportive care drugs market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In North America, U.S. cancer supportive care drugs market is projected to lead the regional market in terms of revenue in 2030.
  • Canada is the fastest growing regional market in North America and is projected to reach USD 551.0 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Cancer Supportive Care Drugs Market Companies

Name Profile # Employees HQ Website

Mexico cancer supportive care drugs market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cancer supportive care drugs market will help companies and investors design strategic landscapes.


Opioids was the largest segment with a revenue share of 26.19% in 2023. Horizon Databook has segmented the Mexico cancer supportive care drugs market based on g-csfs (granulocyte-colony stimulating factors), esas (erythropoiesis stimulating agents), antiemetics, bisphosphonates, opioids, nsaids and others covering the revenue growth of each sub-segment from 2018 to 2030.


Mexico is anticipated to decline during the forecast period. High cancer prevalence and increased demand for chemotherapy associated cancer care drugs in the region are expected to boost the market. However, launch of biosimilars is expected to impede market growth. As per a 2020 report published in US National Library of Medicine, cancer is the third most common cause of mortality in Mexico, with breast and prostate cancers being the most common types in women & men, respectively.

Moreover, the prevalence of cancer has been growing over the past 20 years in the country, mainly due to lifestyle changes and physical inactivity. Increasing geriatric population is expected to triple by 2050 from 2015, which can further increase the prevalence of cancer, as per an article published in Oxford Academic. As per a 2018 article published in NCBI, access to innovative cancer medicines has increased over the years in Mexico.

However, compared to the U.S. and Canada, novel personalized drugs have not yet penetrated in this region, and most of them are not covered under insurance & reimbursement schemes. Thus, chemotherapy is among the most common treatments in the region, which creates demand for chemotherapy-associated cancer supportive care drugs.

Reasons to subscribe to Mexico cancer supportive care drugs market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Mexico cancer supportive care drugs market databook

  • Our clientele includes a mix of cancer supportive care drugs market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Mexico cancer supportive care drugs market , including forecasts for subscribers. This country databook contains high-level insights into Mexico cancer supportive care drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Mexico cancer supportive care drugs market size, by therapeutic class, 2018-2030 (US$M)

Mexico Cancer Supportive Care Drugs Market Outlook Share, 2023 & 2030 (US$M)

Mexico cancer supportive care drugs market size, by therapeutic class, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more